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Abstract
Dendritic cells (DCs) are key activators of cellular immune responses through their capacity to induce naı¨ve T cells and
sustained effector T cell responses. This capacity is a function of their superior efficiency of antigen presentation via MHC
class I and class II molecules, and the expression of co-stimulatory cell surface molecules and cytokines. Maturation of DCs is
induced by microbial factors via pattern recognition receptors such as Toll-like receptors, pro-inflammatory cytokines or
cognate interaction with CD4+ T cells. Here we show that, unexpectedly, the PanDR helper T cell epitope PADRE, a generic T
helper cell antigen presented by a large fraction of HLA-DR alleles, when delivered in particle-bound form induced
maturation of human DCs. The DCs that received the particle-bound PADRE displayed all features of fully mature DCs, such
as high expression of the co-stimulatory molecules CD80, CD86, CD83, the MHC-II molecule HLA-DR, secretion of high levels
of the biologically active IL-12 (IL-12p70) and induction of vigorous proliferation of naı¨ve CD4+ T cells. Furthermore, the
maturation of DCs induced by particle-bound PADRE was shown to involve sphingosine kinase, calcium signaling from
internal sources and downstream signaling through the MAP kinase and the p72syk pathways, and finally activation of the
transcription factor NF-kB. Based on our findings, we propose that particle-bound PADRE may be used as a DC activator in
DC-based vaccines.
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Introduction
Dendritic cells (DCs) are the most efficient and most important
antigen presenting cells (APCs) for T cell priming and induction of
adaptive immune responses [1]. They reside in peripheral tissues
in an immature state and sample their microenvironment by
taking up and processing antigens [2]. Exposure of DCs to
inflammatory mediators such as TNF-a, IL-1-b and IL-6 or
microbial agents such as TLR agonists induces their maturation
with phenotypical and functional changes. The DC activation
marker CD83 [3,4] and receptors for chemokines from secondary
lymphoid organs such as CCR7 [5] are expressed and the co-
stimulatory molecules CD40, CD80 and CD86 are up-regulated
[6]. In addition, fully mature DCs produce pro-inflammatory
cytokines, in particular interleukin (IL)-12, which plays critical
roles in the induction of efficient CD4+ T helper cell (Th) and
sustained effector CD8+ T cell immune responses characterized by
high interferon (IFN)-c production and cytotoxicity [7]. These
changes enable DCs to induce effective adaptive immune
responses. Because of their unique capacities as antigen-presenting
cells, DCs are widely used in cancer immunotherapy and loaded
with tumor-associated antigens as cellular vaccines [8,9]. The
antigens administered hereby are often synthetic peptides such as
epitopes for CD8+ effector T cells. To render such peptides
immunogenic and enhance the potency of the vaccines, CD4+ T
cell help is believed to be important in the initiation of CD8+
effector T cell responses and for establishing T cell memory [10].
In addition to specific MHC class II epitopes, recall antigens and
Pan HLA-DR epitopes (PADREs) have been explored as helper T
cell antigens. PADREs are designed to bind to many different
HLA-DR and thereby to help overcoming the problem of
identifying helper antigens that match the HLA class II of a
particular patient [11]. PADREs have been used together with
different vaccine antigens for induction of cytotoxic effector T cells
in preclinical models [11–15] as well as in clinical trials [15,16]. To
ensure effective induction of DC maturation, combinations of
antigens for coordinated induction of helper and effector T cell
responses are often given together with TLR agonists or pro-
inflammatory cytokines as drivers of functional differentiation of
DC and induction of co-stimulatory cytokines and cell surface
receptors. Moreover, the design of vaccines for effective induction
of T cell-mediated immunity requires, in addition to the before-
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mentioned, carrier systems for transport of the essential vaccine
constituents to and their timely release at dendritic cells. To this
avail we investigated the effects of different essential vaccine
constituents on the induction of prophylactic and therapeutic T
cell-based immune responses. Unexpectedly, particle-bound in
contrast to soluble PADRE was discovered to induce phenotypic
and functional differentiation of immature into fully mature DCs
with strong T cell-stimulatory capacity.
Materials and Methods
Peptides, Lipopeptides and Peptide-loaded Particles
The peptides aK-(L-Cha)-VAAWTLKAAa-Aca-C (PADRE),
influenza matrix protein M158–66 GILGFVFTL (GILG) and
CMV pp65595–603 NLVPMVATV (NLVP) as well as di-acyl-
lipopeptide Pam2Cys-GDPKHPKSF (P2C) were synthesized with
C-terminal tetralysine tags and attached to layer-by-layer coated
silica beads [17] of 1 mm diameter via negative charges on the
outermost polymer layer.
DC Generation and Stimulation
DCs were produced from PBMC using a protocol modified
from [18]. In brief, PBMC from healthy donors were isolated from
buffy coats by Ficoll gradient centrifugation. Cells of the interface
were collected and plated in 6 well plates. Monocytes were allowed
to adhere. After 2 h, non-adherent cells were washed off and the
adherent cells were cultured for 7 days, in serum free AIM-V
culture medium (Invitrogen, Carlsbad, CA, USA) with GM-CSF
(50 ng/mL, R&D Systems, Minneapolis, MN, USA) and IL-4
(50 ng/mL, R&D Systems, Minneapolis, MN, USA). In some
experiments, prior to adherence, the PBMCs were depleted of T
cells by magnetodepletion of CD3+ cells (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany), following the manufacturer’s
instruction. The cultures were kept in a CO2 incubator in a
humidized atmosphere with 8% CO2 at 37uC. On day 5 of
culture, empty particles, particles loaded with peptides as indicated
or free peptides, LPS (1 mg/mL; Sigma-Aldrich, Germany),
ionomycin (1 mg/mL; Sigma-Aldrich, Germany) or an inflamma-
tory cytokine cocktail of IL-1b (10 ng/mL), IL-6 (25 ng/mL)
TNF-a (10 ng/mL; all Strathmann Biotech, Hamburg, Germany)
were added and the culture continued. Where inhibitors were
used, cells were incubated for 2 hours at 37uC with the respective
Figure 1. Phenotypic maturation of dendritic cells (DCs) induced by particles coated with PADRE. iDCs were generated from adherent
PBMCs depleted of T cells. The adherent cells were cultured in serum-free AIM-V medium with GM-CSF and IL-4, harvested on day 5 and incubated
with soluble PADRE, particle-bound PADRE or an inflammatory cytokine cocktail of IL-1b, IL-6 and TNF-a for 2 additional days. On day 7 the cells were
labelled with antibodies for the HLA-DR, CD11c and Lin (cocktail of FITC-conjugated antibodies against the molecules CD3, CD14, CD19 and CD56) for
exclusion, and CD80, CD83 and CD86, and analyzed by flow cytometry. The graphs show mean fold changes with standard error of the expression of
CD80 (A), CD86 (B), CD83 (C), and HLA-DR (D). n = 5; NT: no treatment; Cocktail: IL-1b, IL-6 and TNF-a. * = p,0.05; ** = p,0.01; and *** = p,0.001
comparing the group treated with the indicated compound vs. the group ‘‘NT’’.
doi:10.1371/journal.pone.0063039.g001
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inhibitor prior to the addition of the maturation stimulus. The
specific inhibitors used were SB203580 for p38 MAPK at 20 mM,
triptolide for NF-kB at 100 nM, LY294002 for Pl3K at 10 mM (all
Invivogen, San Diego, Ca, USA), Piceatannol for p72Syk at
25 mM and CK59 for CaMKII at 50 mM (all Calbiochem,
Darmstadt, Germany), BAPTA-AM (membrane-permeating cal-
cium chelator) at 10 mM, D609 for PLC at 100 mM, SKI-II for SK
at 10 mM (all Sigma-Aldrich, Germany) and cyclosporine A for
calcineurin (Fluka Chemie GmbH, Steinheim, Germany) at 2 mM.
Cells were harvested on day 7 and analyzed by flow cytometry or
used for co-cultures with T cell.
CD4+ T Lymphocytes Assays
Naı¨ve and total CD4+ T lymphocytes were isolated from
peripheral blood by magnetosorting. First, CD4+ T cells were
isolated from the PBMCs by negative selection using a commercial
kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)
following the manufacturer’s instruction. In some experiments
the memory/effector population was removed by negative
selection of the CD45RO+ population with PE-labeled monoclo-
nal antibody against the CD45RO (BD Bioscience, Chicago) and
magnetic beads with antibodies to PE (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany). The untouched CD45RA+ naı¨ve
T lymphocytes were labeled with 10 mM CFSE [19] in PBS with
0.1% BSA for 10 min at 37uC followed by 5 min at 4uC. Then the
cells were washed twice in PBS and cultured together with the
autologous DCs in 96 wells plates of 16104 DCs with 26105 T
lymphocytes for 7 days, then harvested and analyzed by flow
cytometry.
Flow Cytometry
To determine DC states and activation, the cell suspensions
were labeled with fluorescent monoclonal antibodies against Lin
(cocktail of FITC-conjugated antibodies against the molecules
Figure 2. Specificity of the DC-inducing activity of particle-bound PADRE. iDCs as in the experiments shown in Figure 1 were incubated
either without stimuli (negative control) or with an inflammatory cytokine cocktail of IL-1b, IL-6 and TNF-a as positive controls, or with particles
without cargo or loaded with GILGFVFTL peptide, NLVPMVATV peptide, PADRE, diacyl-lipopeptide P2C, a mix of both PADRE and P2C or with a
mixture of particles carrying either PADRE or P2C. After two days cultures the cells were labelled with antibodies for the CD11c and Lin (cocktail of
FITC-conjugated antibodies against the molecules CD3, CD14, CD19 and CD56) for exclusion, and CD80, CD83, CD86 and HLA-DR, and analyzed by
flow cytometry. The graphs show fold of expression of the molecules CD80 (A), CD86 (B), CD83 (C) and HLA-DR (D) with standard error. n = 6.
* = p,0.05; ** = p,0.01; and *** = p,0.001 comparing the group treated with the indicated compound vs. the group ‘‘No Treatment’’.
doi:10.1371/journal.pone.0063039.g002
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Figure 3. DCs stimulated with particle-bound PADRE induce vigorous proliferation of naı¨ve CD4+ T cells. Adherent PBMCs previously
depleted of T cells were cultured in presence of GM-CSF and IL-4 for five days and matured by incubation with particles carrying PADRE, P2C, a
mixture of both, or a mixture of particles carrying either PADRE or P2C. After two days, the DCs were washed characterized by flow cytometry as for
the experiments shown in Figures 1 and 2 and then co-cultured with CFSE-labelled naı¨ve CD4+ T cells. After seven days of co-culture, the cells were
harvested and labelled with antibodies to CD4, CD45RA and CD45RO and analyzed by flow cytometry. Proliferation of the T cells was determined by
the reduction of CFSE upon successive cell divisions. The plots show CFSE and CD45RA (A) or CD45RO (B) on gated CD4+ T cells of one of five
independent experiments with cells from five different healthy donors.
doi:10.1371/journal.pone.0063039.g003
Figure 4. Particle-bound PADRE triggers DC maturation by inducing release of calcium from intracellular sources. Mobilization of
intracellular calcium in DCs induced by particles carrying PADRE. iDCs generated as in the experiments shown in Figure 1 and 2 were harvested on
day 5 and labelled with Fluo-3/AM. The DCs were then suspended in medium with or without EDTA and incubated for 10 minutes with empty
particles, particle-bound PADRE, particle-bound P2C, soluble LPS or ionomycin and analyzed by flow cytometry. The graph shows mean fold changes
of Fluo-3 fluorescence with standard error of independent experiments done with cells from three to five different healthy donors (A). *indicates
p,0.05– none vs. stimulus. In (B–C) is shown the effect of the blockade of intracellular calcium on the phenotypic maturation and IL-12p70 secretion
of DCs induced by particle-bound PADRE. 5-day DCs were harvested, labelled or not with BAPTA-AM and incubated with particle-bound PADRE,
particle-bound P2C or ionomycin for 2 more days. On day 7 the cells were labelled with antibodies for the CD80, CD86, CD83 and HLA-DR, and
analyzed by flow cytometry. A representative experiment is shown (B). The supernatant of the stimulation cultures were collected and analyzed for
IL-12p70 by ELISA (C). n = 3.
doi:10.1371/journal.pone.0063039.g004
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CD3, CD14, CD19 and CD56) for exclusion of non-DCs, CD11c,
CD40, CD80, CD83, CD86 and HLA-DR (Caltag Laboratories,
Burlingame, California or BD Bioscience, Chicago). T lympho-
cytes were labeled with antibodies for CD4, CD45RA and
CD45RO. Proliferation of the CD4+ T cells was determined by
flow cytometry after labeling of the cells with CFSE and co-culture
with the differently treated DC. All stained cells were analyzed
with a FACSCalibur flow cytometer (Becton Dickinson, San Jose,
California). The data were processed and displayed using the
CellQuest software (Becton Dickinson, San Jose, California) or
WinMDi (Purdue University, USA; www.purdue.edu).
Measurement of Intracellular Ca2+
Intracellular Ca2+ was measured as described [20] with some
modifications. Briefly, DCs were loaded with 5 mM Fluo-3/AM
(Calbiochem, Darmstadt, Germany) by incubation at 37uC for
30 min under shaking and protection from light. The Fluo-3/AM-
loaded DCs were centrifuged and washed two times. Then the
cells were suspended in culture medium with or without EDTA
(10 mM) and incubated protected from light with empty particles,
particle-bound PADRE, particle-bound P2C, soluble LPS (1 mg/
mL) or ionomycin (1 mg/mL) for 10 min at 37uC and analyzed by
flow cytometry for Ca2+-dependent fluorescence.
ELISA for IL-12p70
The supernatants of the DC cultures were collected after 48 h
incubation with the indicated stimuli and stored at –20uC. IL-
12p70 levels were measured by ELISA Max Standard kit
(BioLegend) in 96-well microtiter plates according to the
manufacturer’s instructions. Results are expressed as pg/mL.
Statistical Analysis
Results were tested for normality by Kolmogorov–Smirnov test.
Comparisons of the results obtained from the different experi-
mental groups were done by ANOVA. Differences with a p,0.05
were considered significant. All statistical analyses were performed
using the Graphpad Software Prism 2.01 for Windows.
Ethics Statement
The reported study was reviewed and approved by the
institutional ethics committee of the Charite´ – Universita¨tsmedizin
Berlin (Protocol # EA1/148/08) and the human materials used
with written informed consent.
Results
Particle-bound but not Soluble PADRE Induces DC
Maturation
In studies aimed at the development of delivery systems that
target vaccine antigens efficiently to dendritic cells in an
immunogenic fashion, we have been testing particles surface-
coated with different compounds. Among these compounds, we
have tested CD8 and CD4 T cell epitopes (viral epitopes for CD8
and Pan-DR for CD4 T cells) and a TLR2/6-agonist, the
dipalmitoyl lipopeptide (P2C). Our experimental set-up relies on
the assessment of the effect of such compounds on immature
dendritic cells (iDCs) generated from plastic-adherent human
peripheral blood monocytes by incubation in medium with IL-4
and GM-CSF. Unexpectedly, particles with PADRE alone were
found to efficiently induce maturation of iDCs. Such an effect was
first evidenced by the expression of the DC activation marker
CD83 and up-regulation of the co-stimulatory molecules CD80
and CD86, and MHC class II (Figure 1). This effect was
dependent on PADRE bound to particles, as the free soluble
peptide was inactive. Maturation of iDCs was not caused by the
particles themselves, as neither particles without peptides nor
particles coated with other peptides such as the influenza matrix
protein epitope GILGFVFTL or the CMV pp65 epitope
NLVPMVATV had any effect (Figure 2). The latter two peptides
are MCH class I-binders, specifically HLA-A*0201-restricted T
cell epitopes. No activation of DCs by particles bearing these
peptides was seen in experiments with iDCs prepared from 20
different HLA-A*0201-positive donors (data not shown). The DC-
stimulating effect of particle-bound PADRE thus seems to be
mediated through MHC class II, not MHC class I. The magnitude
of the DC response was comparable to the effects of the potent
immunostimulatory TLR agonist P2C or a cocktail of the pro-
inflammatory cytokines IL-1b IL-6 and TNF-a (Figure 1 and 2).
PADRE appears to trigger a maximal cellular response of the
DCs, as the addition of P2C either together with PADRE on the
same particles or on separate particles did not further enhance the
expression of activation and co-stimulatory markers by the DCs.
Rather, it seems that the combination of PADRE and the TLR
agonist reduces the effect of either one of these factors. Figures 1
and 2 summarize experiments done with cells from 5 and 6
independent donors, respectively, that all produced comparable
results.
To exclude that T cells contaminating the iDCs preparations
would cause activation of the DCs through cognate interaction
with CD4+ T cells, we eliminated T cells from the DCs cultures
prior to addition of the particles. As shown in Figure S1A and B,
the elimination of T cells had no effect on the DC-stimulatory
capacity of PADRE-loaded particles. Also the DC activation
marker and co-stimulatory molecule CD40, which normally is
induced upon cognate interaction of iDCs with CD4+ T cells and
which via CD40-CD40L interaction leads to mutual activation of
the interacting cells [21], was induced to comparable levels
disregard of whether or not T cell had been eliminated prior to
addition of the particles (Figure S1 B). These results were
reproduced with cells from 4 independent donors in independent
experiments.
DCs Matured through Interaction with Particle-bound
PADRE Stimulate Naı¨ve T cells
DCs stimulated with PADRE-loaded particles appeared to be
functionally fully mature. Incubation of naı¨ve T cells
(CD3+CD4+CD45RA+CD45RO2) with DCs maturated with
particle-bound PADRE induced not only differentiation of the
naı¨ve T cells into effector/memory T cells
(CD3+CD4+CD45RA2CD45RO+) but also vigorous proliferation
of these cells, as determined by flow cytometry by the dilution of
the fluorescent dye CFSE upon successive cell divisions (Figure 3).
These results were reproduced in 5 independent experiments with
cells from different donors and are summarized in Figure S2. The
experiments were done with iDCs rigorously depleted of T cells
before particles were added.
Maturation of DCs Induced by Particle-bound PADRE
Involves Intracellular Calcium Signaling
To elucidate the cellular mechanisms involved in the induction
of DC maturation by particle-bound PADRE, we analyzed the
mobilization of intracellular calcium using Fluo-3 as fluorescent
calcium indicator. Particle-bound PADRE induced an increase of
intracellular calcium, which was not seen in the DCs exposed to
empty particles (Figure 4A). The calcium appears to come from
intracellular stores as depletion of extracellular calcium in the
DC Activation by Particle-Bound MHC-II Ligand
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culture medium with EDTA neither did affect the intracellular
increase nor the activation of the DC (Figure 4A). Blockade of
intracellular calcium using the BAPT-AM, a membrane-perme-
able selective chelator of intracellular Ca2+, completely abrogated
the maturation of the DCs (Figure 4B and C), as evident from the
unaltered low levels of the co-stimulatory molecules CD80 and
CD86, the DC activation marker CD83, MHC class II HLA-DR
and complete absence of IL-12p70 secretion.
Sphingosine Kinase but not PLC Mediates Maturation of
DCs
Phospholipase C (PLC) cleaves phosphatidylinositol 4,5-bispho-
sphate into inositol triphosphate (IP3) and diacylglycerol (DAG).
IP3 binds to its receptor on the endoplasmic reticulum triggering
the release of calcium from these intracellular stores. PLC acts
upstream of calcium release in signal transduction pathways. To
determine whether signaling through PLC plays a role in the
activation of DCs induced by particle-bound PADRE, we
incubated day-5 iDCs with particle-bound PADRE, P2C and
ionomycin with or without a prior 2 h incubation with the PLC
inhibitor D609 at 100 mM. Two days later, the cells were
harvested and analyzed by flow cytometry. There was no effect
of the inhibitor on any of the maturation markers for DCs
indicating that PLC has no role in DC activation by particle-
bound PADRE (Figure 5A). Sphingosine 1-phosphate (S1P) has
been shown to trigger the release of calcium from intracellular
stores independent of IP3. S1P is derived from sphingosine
through the phosphorylation of sphingosine by sphingosine kinase
(SK). We blocked SK by incubating iDCs for 2 hours with the
specific inhibitor SKI-II and then stimulated them with particle-
bound PADRE, P2C or ionomycin. Interestingly, the cells treated
with the SKI-II did not respond to any of the stimuli, pointing at a
SK-dependent pathway of DC activation (Figure 5B).
Maturation of DCs Induced by Particle-bound PADRE
Involves Calmodulin but not Calcineurin
Given the essential role of cytosolic Ca2+ for DC activation by
particle-bound PADRE, we investigated the involvement of the
two mediators of Ca2+ signalling calcineurin and calmodulin.
Inhibition of calcineurin with cyclosporin A had no effect on DCs
Figure 5. Maturation of DCs induced by particle-bound PADRE is via sphingosine kinase but not PLC. Effect of the PLC inhibitor D609
(A) and the sphingosine kinase inhibitor SKI-II (B) on the phenotypic maturation of DCs induced by particle-bound PADRE. Day-5 DCs were incubated
with the inhibitors for 2 hours and then cultured with particle-bound PADRE, particle-bound P2C or ionomycin for 2 days and analyzed by flow
cytometry for CD80, CD86, CD83 and HLA-DR. The histograms show the expression levels of a representative donor of at least three independent
experiments done with cells from three different healthy donors.
doi:10.1371/journal.pone.0063039.g005
Figure 6. Maturation of DCs induced by particle-bound PADRE does not involve calcineurin. Day-5 DCs were collected and incubated
with particle-bound PADRE, particle-bound P2C or ionomycin for additional 2 days in the presence of absence of cyclosporine A. On day 7 the cells
were stained with antibodies for CD80, CD86, CD83 and HLA-DR, and analyzed by flow cytometry. The culture supernatants were analyzed for IL-
12p70 by ELISA. The histograms in (A) show the expression of CD80, CD86, CD83 and HLA-DR of a representative donor, diagram (B) shows the
secretion of IL-12p70. Independent experiments were done with cells from seven different healthy donors.
doi:10.1371/journal.pone.0063039.g006
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activation by particle-bound PADRE (Figure 6); there was still up-
regulation of CD83 and CD86 in the presence of cyclosporin A as
it was the case in DCs stimulated with P2C-bearing particles but
not in DCs incubated with the Ca2+ ionophore ionomycin. Also
the secretion of IL-12p70 was unaltered. On the other hand,
inhibition of the calmodulin pathway with CK59, an inhibitor of
the calmodulin-dependent kinases CamKII, largely abrogated the
expression of CD83 and substantially reduced the up-regulation of
CD80, CD86 and HLA-DR by particle-bound PADRE (Figure 7).
Partial inhibition of ionomycin-mediated induction of CD83 was
seen; otherwise little to no effect was observed when DCs were
incubated with ionomycin or particle-bound P2C in the presence
of CK59, suggesting that different Ca2+-dependent pathways are
involved in DC activation by the three stimulators tested. Thus,
induction of DC maturation by particle-bound PADRE appears to
involve calmodulin, whereas calcineurin seems to play a major role
in the activation of DC by ionomycin. The TLR 2/6 agonist P2C
acts through a different mechanism.
Kinase Signaling in DC Activation by Particle-bound
PADRE
The kinases p72Syk, PI3K and p38 MAPK have been described
to play a significant role in DC maturation induced by different
stimuli [22,23] and the pathway they are involved in are
interlinked with calcium signaling [24–26]. DC activation by
particle-bound PADRE was affected by the inhibitors piceatannol
and SB203580 that specifically block p72Syk and p38 MAPK,
respectively, whereas the PI3K inhibitor LY294002 had little to no
effect on the expression of the activation markers and co-
stimulatory molecules, and the secretion of IL-12p70 by the
DCs (Figure 8). The pattern of inhibition was similar to the effects
of these factors on DC stimulation by the TLR 2/6 agonist P2C
but different from LPS stimulation. Expectedly, blockade of the
downstream transcription factor NF-kB with triptolide, an
inhibitor of IkB degradation, had significant effects on the
activation of the DC related to the activation markers and co-
stimulatory molecules but not to the same extent on IL-12
secretion.
Figure 7. Maturation of DCs induced by particle-bound PADRE involves CaMKII. Effect of the CaMKII inhibitor CK59 on the phenotypic
maturation of DCs induced by particle-bound PADRE. Day-5 DCs were cultured with particle-bound PADRE, particle-bound P2C or ionomycin for 2
days and analyzed by flow cytometry for CD80, CD86, CD83 and HLA-DR. The histograms show the expression levels of a representative donor of four
independent experiments done with cells from four different healthy donors.
doi:10.1371/journal.pone.0063039.g007
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Figure 8. Effect of the specific inhibitors of kinase signaling on the phenotypic maturation of DCs induced by particle-bound
PADRE. Day-5 DCs were incubated for 2 hours with inhibitors for p72 Syk, PI3K, p38 MAPK or NF-kB after which particle-bound PADRE, particle-
bound P2C or soluble LPS were added and the cultures continued for 2 more days. On day 7 the cells were analyzed by flow cytometry for expression
of CD80, CD86, CD83 and HLA-DR and their culture supernatant by ELISA for IL-12p70. The graphs show fold change of expression of CD80 (A), CD86
(B), CD83 (C) and HLA-DR (D), or IL-12p70 levels in the supernatants (E) with standard error of 7 independent experiments with cells from 7 different
healthy donors. * = p,0.05; ** = p,0.01; and *** = p,0.001 comparing the group treated with stimulus only vs. the groups treated with stimulus plus
the specific inhibitor.
doi:10.1371/journal.pone.0063039.g008
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Discussion
The results of the investigations described herein demonstrate
that the MHC class II-binding pan-DR epitope PADRE, when
administered in particle-bound form, acts directly on iDCs to
induce their phenotypic and functional differentiation into mature
DCs with potent T cell-stimulating capacity. Unlike DC activation
by cognate antigen-dependent interaction with T cells, this effect
was T cell-independent. The receptor for PADRE is HLA-DR [11
and 12], a MHC class II molecule. There is a growing body of
evidence that MHC class II molecules are involved in signal
transduction [23,27–32]. Some antibodies with specificities for
these molecules can activate MHC class II-expressing cells when
cross-linking the molecules [27]. Also the MHC-II-ligand LAG-3,
expressed on the surface of activated T cells was shown to induce
DCs maturation [23]. The finding that DC activation by PADRE
requires its coupling to particles could point into the same
direction, that is, particle-bound PADRE may crosslink HLA-DR
and thereby induces signaling into the cells with subsequent
activation and maturation of immature into fully mature DCs.
This signal is, as the experiments presented with this report show,
similar in strength and effect on the DCs as signals induced by the
known strong immune stimulator P2C, a TLR 2/6 agonist, or a
cocktail of proinflammatory cytokines selected for their maximal
effects on DCs.
Maturation of DCs involves a number of different signaling
molecules and pathways [22,33]. Triggering of DCs by various
different ligands was shown to lead to a rise of intracellular calcium
[33] pointing to a key role of calcium-modulated signaling
pathways in the maturation process. Several different stimuli lead
to increase of intracellular calcium in DCs [33], and calcium
ionophores induce DCs maturation. Also exposure of DCs to
particle-bound PADRE induced a raise in the intracellular
calcium. This calcium was released from intracellular sources
which, however, is not mediated through IP3 as in most other
investigated situations, but through sphingosin phosphate. Sphin-
gosin kinase, the enzyme that phosphorylates sphingosin, has been
linked to signal transduction from MHC class II molecules. It is
prominently expressed in DCs [34] which makes its involvement
also in transduction of signals from other stimuli possible.
Calcium exerts its effects by binding to and modulating the
function or activity of a variety of different proteins, some
enzymes, some themselves modulators of the activity of other
proteins [35]. Calcineurin [33,35] and calmodulin [35,36] are the
most prominent mediators of calcium signaling. Calcineurin has
been implicated in the activation of DCs, among others through
activation of the transcription factor NFAT [35]. However, it
played no role in the activation and maturation of DCs triggered
by particle-bound PADRE. In contrast to calcineurin, calmodulin
was shown to be involved in the activation of DCs by particle-
bound PADRE, which is in agreement with recent reports of its
involvement in DC maturation induced through other stimuli
[37]. One of the target molecules of calcium-activated calmodulin
is the calmodulin-dependent kinases II (CamKII). CamKII
activation has been related to the activation of p38 MAPK [38]
and NF-kB [39] which both have been shown to play important
roles in DC maturation [22,23]. In agreement with that, we show
here that the inhibition of CamKII, p38 MAPK and NF-kB
blocked the activation of DCs by particle-bound PADRE.
Based on the results of the experiments reported herein, we
suggest the following model for the mechanism of DC activation
by particle-bound PADRE. Particles with bound PADRE may
crosslink HLA-DR at the surface of immature DCs, which triggers
activation of the sphingosin kinase. The product of sphingosin
kinase, phosphosphingosin, mediates calcium release from intra-
cellular sources, which binds to and activates calmodulin, and via
CamKII activates both the MAPK and the p72syk signaling
pathways, which ultimately leads to activation of NF-kB and
maybe other transcription factors and as result to activation of the
DCs. The need to address both the p72syk and the MAPK
signaling pathways for full activation and maturation of DCs has
been suggested before and is confirmed with the present report.
The finding of DC activation through particle-bound particle
reveals interesting new facets of MHC class II and its molecular
cell biology and may have practical implications for the design of
immune stimulators and vaccines. Particle-bound PADRE could
be used as a new class of immunological adjuvant mediating T
cell-dependent immune reactions where it may double as DC
activator and helper T cell antigen. PADRE is often used in cancer
immunotherapy protocols in the latter capacity to support
induction of sustained CD8+ effector T cell responses, but so far
only in free soluble form [13–16]. Binding to particles, as we show
here may enhance its effect and lead to induction of additional DC
functions known to be essential or at least highly beneficial for the
induction of effective and sustained CD8+ effector T cell responses.
Supporting Information
Figure S1 Effects of T cells on the maturation of iDCs
induced by particle-bound PADRE. PBMCs separated by
Ficoll gradient centrifugation were depleted of T cells or not,
enriched for monocytes by adherence and cultured in serum-free
AIM-V with IL-4 and GM-CSF. A) Percentage of CD4+ T cells
present in one representative of four independent DC cultures.
The panel on the left shows the dot plot from a DC culture where
the T cells were not depleted, the right panel a DC culture where
the T cells were depleted prior to culturing the monocytes for DC
production. B) Phenotype of DCs from cultures previously
depleted of T cells (white bars) or not (gray bars) prior to
maturation with an inflammatory cytokine cocktail of IL-1b, IL-6
and TNF-a, particle-bound P2C or particle bound PADRE. The
graphs show means with standard error of MFI for HLA-DR,
CD40, CD80, CD83 and CD86, respectively, from four
independent experiments with DCs prepared from PBMC of four
different healthy donors.
(TIF)
Figure S2 Proliferation of CD4+ T cells incubated with
DCs matured with particle-bound PADRE, P2C or both,
or an inflammatory cytokine cocktail of IL-1b, IL-6 and
TNF-a. Plastic-adherent PBMCs previously depleted of T cells
were cultured in presence of GM-CSF and IL-4 for 5 days and
then matured with the stimuli as indicated in the graph. The DCs
obtained from the cultures were then cocultured with CFSE-
labelled naı¨ve CD4+ T cells for seven days. The cells were then
stained for CD4, CD45RA and CD45RO, and analyzed by flow
cytometry for CFSE levels as indicator for cell proliferation. The
values shown refer to the percentage of CD4+CFSElow cells and
are the means of five independent experiments done with cells
from five different healthy donors.
(TIF)
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